Abstract
The recent article by Lin et al.,1 described blood neurofilament light chain (NfL) both as a diagnostic biomarker to distinguish between controls, patients with Parkinson disease (PD), and patients with multiple system atrophy (MSA) and as a progression biomarker for PD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
